Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen

Brent Blumenstein, Fred Saad, Sebastien Hotte, Kim N Chi, Bernhard Eigl, Martin Gleave, Cindy Jacobs, Brent Blumenstein, Fred Saad, Sebastien Hotte, Kim N Chi, Bernhard Eigl, Martin Gleave, Cindy Jacobs

Abstract

Elevated levels of clusterin (CLU), a stress-induced and secreted cytoprotective chaperone, are associated with advanced tumor stage, metastasis, treatment resistance, and adverse outcome in several cancers. Custirsen, a second-generation antisense oligonucleotide, inhibits CLU production in tumor cells and reduces serum CLU levels. A Phase 2 study evaluated custirsen in combination with second-line chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC) who had progressed while on or within 6 months of first-line docetaxel-based chemotherapy. Exploratory analyses evaluated serum CLU levels during custirsen treatment and correlative clinical effects on prostate-specific antigen (PSA) response, overall survival, and any relationship between serum CLU and PSA. Men with mCRPC were treated with mitoxantrone/prednisone/custirsen (MPC, n = 22) or docetaxel retreatment/prednisone/custirsen (DPC plus DPC-Assigned, n = 45) in an open-label, multicenter study. Subject-specific profiles of PSA and serum CLU levels during treatment were characterized using statistical modeling to compute subject-specific summary measures; these measures were analyzed for relationship to survival using proportional hazard regression. Estimated individual serum CLU response profiles were scored as below or at/above the median level for the population through 100 days postrandomization. Median survival was longer for subjects scoring below the median serum CLU level compared with subjects at/above the median level, respectively (MPC: 15.1 months vs. 6.2 months; DPC-Pooled: 17.0 months vs. 12.1 months). Lowered serum CLU levels during custirsen treatment when in combination with either chemotherapy regimen were predictive of longer survival in mCRPC. These results support further evaluation of serum CLU as a therapeutic biomarker.

Trial registration: ClinicalTrials.gov NCT00327340.

Keywords: Antisense oligonucleotide; chemotherapy; clusterin; custirsen; mCRPC.

Figures

Figure 1
Figure 1
Role of CLU in cancer cell survival.
Figure 2
Figure 2
Serial serum CLU and log PSA values by time. Shown is a sample from the graphs created to assess the general shape of the individual longitudinal outcomes. These graphs also show the fit of the quadratic model to each individual's data.
Figure 3
Figure 3
Serum CLU features and mean change by treatment group. For each group the extracted features of the 100-day CLU profile are plotted. These graphs show the general trend in response to the implementation of intervention.
Figure 4
Figure 4
Log PSA features and mean change by treatment group. For each group the extracted features of the 100-day log(PSA) profile are plotted. These graphs show the general trend in response to the implementation of intervention.
Figure 5
Figure 5
Kaplan–Meier estimates of survival by treatment group. The proportional hazard regression modeling (Table 2) suggested that Kaplan–Meier estimates from the four subgroups shown are a good representation of the data. In particular note that the difference between high versus low CLU response applies regardless of the type of chemotherapy.

References

    1. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate. 2002;50:179–188.
    1. Flanagan L, Whyte L, Chatterjee N, Tenniswood M. Effects of clusterin over-expression on metastatic progression and therapy in breast cancer. BMC Cancer. 2010;10:107.
    1. Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin. Cancer Res. 2002;8:3276–3284.
    1. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia. 2001;3:360–367.
    1. Loison F, Debure L, Nizard P, Michel P, le Goff D, le Drean Y. Up-regulation of the clusterin gene after proteotoxic stress: implication of HSF1-HSF2 heterocomplexes. Biochem. J. 2006;395:223–231.
    1. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J. Biol. Chem. 1999;274:6875–6881.
    1. Yerbury JJ, Poon S, Meehan S, Thompson B, Kumita JR, Dobson CM, et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 2007;21:2312–2322.
    1. Nizard P, Tetley S, Watrin Y, Le Drean T, Wilson P, Le Goff MR, et al. Stress-induced retrotranslocation of clusterin/ApoJ into the cytosol. Traffic. 2007;8:554–565.
    1. Trougakos IP, Lourda M, Antonelou MH, Kletsas D, Gorgoulis VG, Papassideri IS, et al. Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clin. Cancer Res. 2009;15:48–59.
    1. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY. Clusterin inhibits apoptosis by interacting with activated Bax. Nat. Cell Biol. 2005;7:909–915.
    1. Ammar H, Closset JL. Clusterin activates survival through the phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem. 2008;283:12851–12861.
    1. Lee KB, Jeon JH, Choi I, Kwon OY, Yu K, You KH. Clusterin, a novel modulator of TGF-beta signaling, is involved in Smad2/3 stability. Biochem. Biophys. Res. Commun. 2008;366:905–909.
    1. Zoubeidi A, Ettinger S, Beraldi E. Clusterin facilitates COMMD1 and I-kB degradation to enhance NF-kB activity in prostate cancer cells. Mol. Cancer Res. 2010;8:119–130.
    1. Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res. 2000;60:2547–2554.
    1. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res. 2000;60:170–176.
    1. Miyake H, Hara S, Zellweger T, Kamidono S, Gleave ME, Hara I. Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells. Mol. Urol. 2001;5:105–111.
    1. Miyake H, Hara I, Kamidono S, Gleave ME. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin. Cancer Res. 2001;7:4245–4252.
    1. Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int. 2008;102:389–397.
    1. Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J. Natl. Cancer Inst. 2000;92:34–41.
    1. Miyake H, Muramaki M, Furukawa J, Kurahashi T, Fujisawa M. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. Urology. 2010;75:454–459.
    1. Hazzaa SM, Elashry OM, Afifi IK. Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder. Pathol. Oncol. Res. 2010;16:101–109.
    1. Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, et al. Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG Trial P-06c. Clin. Cancer Res. 2011;17:5765–5773.
    1. Laskin JJ, Nicholas G, Lee C, Gitlitz B, Vincent M, Cormier Y, et al. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J. Thorac. Oncol. 2012;7:579–586.
    1. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl. Cancer Inst. 2005;97:1287–1296.
    1. Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, et al. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin. Cancer Res. 2008;14:833–839.
    1. Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2010;28:4247–4254.
    1. Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP, et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J. Pharmacol. Exp. Ther. 2001;298:934–940.
    1. Muramaki M, So A, Hayashi N, Sowery R, Miyake H, Fujisawa M, et al. Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. BJU Int. 2009;103:384–390.
    1. July LV, Beraldi E, So A, Fazli L, Evans K, English JC, et al. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol. Cancer Ther. 2004;3:223–232.
    1. Hoeller C, Pratscher B, Thallinger C, Winter D, Fink D, Kovacic B, et al. Clusterin regulates drug-resistance in melanoma cells. J. Invest. Dermatol. 2005;124:1300–1307.
    1. So A, Sinnemann S, Huntsman D, Fazli L, Gleave M. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol. Cancer Ther. 2005;4:1837–1849.
    1. Senn S, Stevens L, Chaturvedi N. Repeated measures in clinical trials: simple strategies for analysis using summary measures. Statist. Med. 2000;19:861–877.
    1. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 2003;21:1232–1237.
    1. Yang GF, Li XM, Xie D. Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int. J. Gynecol. Cancer. 2009;19:1342–1346.
    1. Wei L, Xue T, Wang J, Chen B, Lei Y, Huang Y, et al. Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer. Int. J. Cancer. 2009;125:791–806.
    1. Miyake H, Hara S, Arakawa S, Kamidono S, Hara I. Over expression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma. J. Urol. 2002;167:703–706.
    1. Ekici S, Eroğlu A, Doğan Ekici AI, Türkeri L. Clusterin immunoreactivity as a predictive factor for progression of non-muscle-invasive bladder carcinoma. Urol. Int. 2011;86:31–35.
    1. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jr, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99–16. J. Natl. Cancer Inst. 2006;98:516–521.
    1. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J. Clin. Oncol. 1983;1:710–719.
    1. Box GEP, Draper NR. Empirical model building and response surfaces. New York, NY: John Wiley & Sons; 1987.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅